Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 2
2010 2
2011 2
2012 3
2013 5
2014 3
2015 4
2016 2
2017 4
2019 5
2020 6
2021 5
2022 2
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: hiwase dk. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ, Wei AH. Loo S, et al. Among authors: hiwase dk. Blood. 2023 Dec 7;142(23):1960-1971. doi: 10.1182/blood.2023020301. Blood. 2023. PMID: 37647654 Free PMC article. Clinical Trial.
Myeloid neoplasms with germline DDX41 mutation.
Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL. Cheah JJC, et al. Among authors: hiwase dk. Int J Hematol. 2017 Aug;106(2):163-174. doi: 10.1007/s12185-017-2260-y. Epub 2017 May 25. Int J Hematol. 2017. PMID: 28547672 Review.
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.
Fox LC, McQuilten ZK, Firkin F, Fox V, Badoux X, Bajel A, Barbaro P, Cole-Sinclair MF, Forsyth C, Gibson J, Hiwase DK, Johnston A, Mills A, Roncolato F, Sutherland R, Szer J, Ting SB, Vilcassim S, Young L, Waters NA, Wood EM; Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry (AAR) Investigators. Fox LC, et al. Among authors: hiwase dk. Best Pract Res Clin Haematol. 2023 Dec;36(4):101516. doi: 10.1016/j.beha.2023.101516. Epub 2023 Oct 23. Best Pract Res Clin Haematol. 2023. PMID: 38092475 Free article. Review.
Mobilisation strategies for normal and malignant cells.
To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, Antonenas V, Rice AM, Gottlieb D, Mills AK, Rasko JE, Larsen S, Beligaswatte A, Nilsson SK, Cooney JP, Cambareri AC, Lewis ID. To LB, et al. Among authors: hiwase dk. Pathology. 2011 Oct;43(6):547-65. doi: 10.1097/PAT.0b013e32834a9eb8. Pathology. 2011. PMID: 21921732 Review.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. Shah MV, et al. Among authors: hiwase dk. Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x. Blood Cancer J. 2023. PMID: 37041128 Free PMC article.
53 results